GTC now complements our comprehensive molecular profiling by offering Immunohistochemistry (IHC) testing for PD-L1 and FOLR1.
Our clients now have the option to order IHC when they order our solid tumor molecular profiling (GTC-Solid Tumor Profile PLUS).
PD-L1 – can identify patients who would be candidates for Pembrolizumab (Keytruda), Nivolumab (Opdivo), Atezolizumab (Tencentriq) and other immunotherapies
FOLR1 – can identify patients who would be candidates for Mirvetuximab soravtansine (Elahere)
Don’t accept partial results, order GTC’s comprehensive next-gen sequencing profiles which includes DNA and RNA analysis detecting known and novel fusions, gene expression, viral HPV and EBV RNA and more.
Adding Immunohistochemistry (IHC) testing for PD-L1 and FOLR1 to solid tumor molecular profiling services we provide our clients with even more comprehensive information about their patients’ tumors.
PD-L1 is a protein that is overexpressed in many types of cancer and is used as a biomarker to determine eligibility for certain immunotherapies.
FOLR1 is a folate receptor that is overexpressed in some tumors and can be targeted with folate-based drugs. By adding IHC testing for these biomarkers, GTC can provide more personalized treatment options for cancer patients based on their specific tumor characteristics.
At GTC, we are dedicated to providing more personalized treatment options for cancer patients based on their specific tumor characteristics. Our informatics tools utilize artificial intelligence with sophisticated algorithms to interpret complex data sets, making our IHC testing capabilities unmatched in the market today.
Combined with our comprehensive next-generation sequencing profiles that include DNA and RNA analysis detecting known and novel fusions, gene expression, viral HPV and EBV RNA, and more, the addition of IHC testing for PD-L1 and FOLR1 has made GTC even better equipped to provide state-of-the-art cancer diagnostics.
We remain committed to advancing cancer diagnostics and providing the best testing options for physicians and their patients. With this new capability, we are excited to continue our mission of improving outcomes for cancer patients.
This Hematology Profile™ is designed to profile the molecular abnormalities in various hematologic neoplasms. The test analyzes the DNA of 177 genes that are associated with hematologic cancers including:
-Myelodysplastic syndrome (MDS)/Chronic myelomonocytic leukemia (CMML): The Hematology Profile is used for stratifying patients, determining prognosis and selecting therapy. This assay will not only determine the aggressiveness and prognosis of the MDS but will also determine if the patient has reactive cytopenia and will distinguish between CHIP (Clonal Hematopoiesis of Indeterminate Potential) or CCUS (Clonal Cytopenia of Unknown Significance) and MDS.
-VEXAS Disease: Recently described VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) is caused by mutations in the UBA1 gene. This is an adults-onset fatal disease that may present as myelodysplastic syndrome, aplastic anemia or multiple myeloma, but characterized by fevers, low white cell count, vacuoles in bone marrow cells, dysplastic bone marrow, pulmonary inflammation, chondritis, and vasculitis. Detecting the presence of mutations in the UAB1 gene is the only way for confirming the diagnosis of VEXAS disease.
-Acute Myeloid Leukemia (AML): The Hematology Profile helps in the diagnosis of AML and distinguish between De Novo AML vs secondary AML. It also helps in determining eligibility for treatment with FLT3 and IDH1/2 inhibitors. For a complete evaluation of translocations including all types of APL, Inv16, and t(8,21) and NUP98 translocations, we recommend ordering the GTC-Hematology PLUS panel.
-Myeloproliferative Neoplasms (MPN): This includes quantitative analysis of all exons of JAK2, CALR, and MPL.
-Lymphoma: Analysis of mutations reported in various types of lymphoma, including follicular, DLBCL, CLL, and T-cell lymphoma. However, for a complete evaluation of lymphoma including determining double hit lymphoma and diagnosis of ABC vs GBC, RNA adding the ordering GTC-Hematology PLUS panel is recommended.
-Multiple Myeloma: This Hematology Profile detects mutations in the coding sequence of genes frequently mutated in MM, but for a thorough evaluation, we recommend ordering GTC-Hematology PLUS to cover expression abnormalities and chromosomal translocations.
Clonal Hematopoiesis of Indeterminate Potential (CHIP): Distinguish CHIP from clinically active and relevant hematologic neoplasm based on an internally developed algorithm using variant allele frequency, chromosomal structural abnormalities, clinical and laboratory data and longitudinal data. This distinction is particularly important when evaluating minimal residual disease and in the presence of other neoplastic process.
Turn Around Time: 5-7 days